Back to search

National and Kapodistrian University of Athens

Μη επεμβατική προγεννητική διάγνωση του συνδρόμου Down του εμβρύου στο αίμα της εγκύου με μεθόδους βασιζόμενες στη διαφορική μεθυλίωση DNA του εμβρύου και της μητέρας

Abstract

dc:description

Down Syndrome (or Trisomy 21) (OMIM190685) has an incidence of 1 in 700 births in all populations worldwide, and is considered to be the most frequent etiology of mental retardation. Non-invasive prenatal screening is currently based on the use of ultrasound scans combined with maternal serum biochemical markers, whereas prenatal diagnosis of high risk pregnancies is performed by karyotyping and/or DNA analysis of fetal cells obtained via chorionic villus sampling, amniocentesis, or cordocentesis. As the above procedures are invasive and associated with ~1% risk of fetal loss, there is an urgent need for the development of accurate, stand-alone non-invasive strategies. Since the discovery of the circulating cell free fetal DNA (cffDNA), which was found to be of placental origin, large scale studies have been ongoing to develop non-invasive prenatal diagnostic methodologies. Recently, our team has combined a newly developed methodology known as Methylated DNA Immunoprecipitation (MeDIP) with high-resolution tiling oligonucleotide array, to identify the differences in DNA methylation between maternal and fetal DNA across the chromosomes of interest (chromosomes 13, 18, 21, X and Y). The data generated was used for the development and validation of the first universal non-invasive prenatal diagnosis (NIPD) for trisomy 21, using MeDIP real time qPCR with a selected subset of DMRs on chromosome 21. In this PhD study, we estimated the sensitivity and specificity of the NIPD21 diagnostic test (version 1) with the application of the test on 100 blinded blood samples. The 60 normal and 40 abnormal testing samples are correctly classified showing 100% accuracy. Then, we present new data of our MeDIP real time qPCR NIPD method with an extensive re-evaluation of the efficiency of each DMR included in the discriminant analysis, the development of an improved version (v1.1) of the diagnostic formula, as well as a new and larger validation blind study. The discrimination of normal from trisomy 21 pregnancies is based on the quantification of the extra copy of chromosome 21. Therefore, the regions on chromosome 21 chosen for further investigation should be free of CNVs, as these would interfere with the interpretation of the results and may lead to misdiagnosis. Upon searching the DGV database, we initially investigated whether the 12 selected DMRs are located within regions of known CNVs. The results showed that four out of the 12 DMRs are located within chromosomal regions with CNVs. EP8 and EP11 were used for the construction of the first diagnostic formula (version 1) and therefore it was necessary to revise the original diagnostic formula (version 1.1) by excluding the DMRs located within CNVs.The DMRs which were free of CNVs or segmental duplications were used to design the new diagnostic formula, version 1.1 (v1.1). The implementation of the discriminant analysis of 75 cases showed that seven out of the eight - free of CNVs - DMRs, entered the final model of the prediction equation (diagnostic formula). A validation blind study was performed on 100 additional samples including 25 trisomy 21 cases and 75 normal cases. The results showed 99.2% specificity with 95% CI [95.62, 99.98] and 100% sensitivity with 95%CI [92.89, 100.00] of our NIPD21. All cases were correctly classified with the exception of one normal sample which gave a grey zone-false positive result. In addition to the above, we extensively examined, based on very strict criteria, more than 2000 DMRs on chromosome 21 to reassure that the DMRs used in our method are the best and to create a group of DMRs available for further examination of inconclusive cases.Furthermore, we tried to evaluate and optimize the protocol of the method. We managed to omit the LM-PCR step by using absolute quantification instead of relative quantification and to merge time consuming stages of the MeDIP. We also applied the NIPD21 on plasma samples instead of whole blood samples and we replaced the EDTA tubes by alternative tubes with better results. Finally, we made some constructive changes to the protocols, the equipment and the enzymes used in the test to reduce the time, the cost and the labor.The MeDIP real-time qPCR-based approach (version 1.1) is in advantage compared to the other technologies provided as it is more accurate, sensitive, faster, simpler and cost-effective. We speculate that NIPD tests will soon expand to other common and rare causative copy number change (CNV) and mutation-associated diseases, such as aneuploidies for chromosomes 13, 18, X and Y, small size rearrangements and diseases caused by single gene mutations.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2012

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tsaliki, Evdokia
  • Τσαλίκη, Ευδοκία

Subjects

dc:subject × 9

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/38175

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tsaliki, Evdokia; Τσαλίκη, Ευδοκία. Μη επεμβατική προγεννητική διάγνωση του συνδρόμου Down του εμβρύου στο αίμα της εγκύου με μεθόδους βασιζόμενες στη διαφορική μεθυλίωση DNA του εμβρύου και της μητέρας. National and Kapodistrian University of Athens, 2012. http://hdl.handle.net/10442/hedi/38175